KR20110092351A - 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드 - Google Patents

방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드 Download PDF

Info

Publication number
KR20110092351A
KR20110092351A KR1020117015534A KR20117015534A KR20110092351A KR 20110092351 A KR20110092351 A KR 20110092351A KR 1020117015534 A KR1020117015534 A KR 1020117015534A KR 20117015534 A KR20117015534 A KR 20117015534A KR 20110092351 A KR20110092351 A KR 20110092351A
Authority
KR
South Korea
Prior art keywords
radiation
active corticosteroid
chemotherapy
damage
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117015534A
Other languages
English (en)
Korean (ko)
Inventor
로버트 엔. 브레이
Original Assignee
솔리제닉스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 솔리제닉스, 인크. filed Critical 솔리제닉스, 인크.
Publication of KR20110092351A publication Critical patent/KR20110092351A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1020117015534A 2008-12-08 2009-12-08 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드 Ceased KR20110092351A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12078508P 2008-12-08 2008-12-08
US61/120,785 2008-12-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167036277A Division KR101783577B1 (ko) 2008-12-08 2009-12-08 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드

Publications (1)

Publication Number Publication Date
KR20110092351A true KR20110092351A (ko) 2011-08-17

Family

ID=42310112

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117015534A Ceased KR20110092351A (ko) 2008-12-08 2009-12-08 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드
KR1020167036277A Expired - Fee Related KR101783577B1 (ko) 2008-12-08 2009-12-08 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167036277A Expired - Fee Related KR101783577B1 (ko) 2008-12-08 2009-12-08 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드

Country Status (12)

Country Link
US (3) US20100183749A1 (enExample)
EP (2) EP2902031B1 (enExample)
JP (2) JP5709266B2 (enExample)
KR (2) KR20110092351A (enExample)
CN (2) CN102307466A (enExample)
AU (1) AU2009333538B2 (enExample)
CA (1) CA2745930C (enExample)
DK (2) DK2373160T3 (enExample)
IL (1) IL213411A (enExample)
NZ (1) NZ593694A (enExample)
SG (2) SG10201704531XA (enExample)
WO (1) WO2010077681A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
US9017644B2 (en) 2008-11-07 2015-04-28 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
PL3441458T3 (pl) 2009-02-03 2023-11-06 Koninklijke Nederlandse Akademie Van Wetenschappen Podłoże do hodowli nabłonkowych komórek macierzystych i organoidów zawierających wspomniane komórki macierzyste
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US8912323B2 (en) 2009-10-30 2014-12-16 The Regents Of The University Of Michigan Multifunctional small molecules
WO2012112791A1 (en) * 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
EP2854850B1 (en) * 2012-05-25 2021-05-26 Sloan Kettering Institute For Cancer Research Compositions for treating or preventing radiation disease and gi syndrome
US20160074400A1 (en) * 2012-08-06 2016-03-17 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
WO2014059068A1 (en) * 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
US9827290B2 (en) 2013-02-28 2017-11-28 The Regents Of The University Of Michigan Compositions and methods relating to induction of intestinal stem cell homeogenesis and/or regeneration
US9850279B2 (en) * 2013-09-13 2017-12-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
US11311598B2 (en) 2013-09-13 2022-04-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
US9439947B2 (en) 2014-03-28 2016-09-13 Albert Einstein College Of Medicine, Inc. Therapy for radiation-induced lung injury
ES3035970T3 (en) * 2014-10-02 2025-09-11 Cytosorbents Corp Use of gastrointestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
WO2017011457A1 (en) * 2015-07-12 2017-01-19 The University Of Tennessee Research Foundation Compositions and methods for protecting colonic epithelial barrier function
WO2017119988A2 (en) * 2015-12-10 2017-07-13 Memorial Sloan Kettering Cancer Center Radioprotection by wnt activation
CN107753932A (zh) * 2016-08-22 2018-03-06 中国辐射防护研究院 Kgf在制备治疗或预防放射性肠炎药物中的用途
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
US20020086857A1 (en) * 2000-09-15 2002-07-04 Mcdonald George B. Method of long-term treatment of graft-versus-host disease using topical active corticosterioids
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
CA2441007C (en) * 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
CN101060848B (zh) * 2004-12-30 2011-06-22 索利吉尼克斯公司 用二丙酸倍氯米松和泼尼松治疗移植物抗宿主病和白血病
JP4839436B2 (ja) * 2005-11-02 2011-12-21 国立大学法人徳島大学 消化管粘膜保護剤、カベオリン遺伝子発現促進剤及び抗ストレス剤
US20070293458A1 (en) 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
US20080233088A1 (en) * 2007-02-16 2008-09-25 Varian Medical Systems Technologies, Inc. Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation
DK3354276T3 (da) * 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation

Also Published As

Publication number Publication date
EP2373160A4 (en) 2012-06-13
JP5709266B2 (ja) 2015-04-30
JP2015038155A (ja) 2015-02-26
DK2373160T3 (en) 2018-01-02
IL213411A0 (en) 2011-07-31
EP2373160B1 (en) 2017-10-25
CN102307466A (zh) 2012-01-04
IL213411A (en) 2016-12-29
US20200155571A1 (en) 2020-05-21
JP5905562B2 (ja) 2016-04-20
KR101783577B1 (ko) 2017-09-29
CA2745930A1 (en) 2010-07-08
NZ593694A (en) 2013-09-27
KR20170001735A (ko) 2017-01-04
SG171997A1 (en) 2011-07-28
EP2902031A1 (en) 2015-08-05
CA2745930C (en) 2017-05-02
DK2902031T3 (en) 2019-01-14
US20170333448A1 (en) 2017-11-23
US20100183749A1 (en) 2010-07-22
CN106692162A (zh) 2017-05-24
EP2902031B1 (en) 2018-10-24
AU2009333538B2 (en) 2014-09-11
SG10201704531XA (en) 2017-07-28
JP2012511034A (ja) 2012-05-17
WO2010077681A1 (en) 2010-07-08
AU2009333538A1 (en) 2011-07-14
EP2373160A1 (en) 2011-10-12
HK1207582A1 (en) 2016-02-05

Similar Documents

Publication Publication Date Title
KR20110092351A (ko) 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드
KR101628448B1 (ko) 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법
JP6755865B2 (ja) 血球減少症の治療またはその持続時間の低減のためのホルボールエステル組成物およびその使用方法
CN115501231B (zh) 预防和/或治疗肝癌的联用药物组合物及其应用
US20050233966A1 (en) Methods for controlling angiogenesis and cell proliferation
Early et al. Mitomycin C in the treatment of metastatic transitional cell carcinoma of urinary bladder
KR101544222B1 (ko) 유두상 신세포암에서의 템시로리무스의 항종양 활성
HK1207582B (en) Topically active steroid for use in radiation injury
HK1162861B (en) Topically active steroids for use in radiation injury
HK1162861A (en) Topically active steroids for use in radiation injury
EP3079709A1 (en) Ephedra alata extracts and methods of use thereof
CN108379557A (zh) 使用白介素因子-37治疗特发性肺纤维化
TWI439266B (zh) 對癌症之治療有貢獻的方法和組成物
WO2005025489A2 (en) Therapeutic use of g53135-05(fgf-20) in radiation protection
CN107929295A (zh) 一种罗格列酮的新用途及含罗格列酮的抗肿瘤药物组合
UA113883U (xx) Спосіб лікування пневмонії на тлі лейкозів глутоксимом

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110705

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141014

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160127

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160812

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20160812

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160627

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20141014

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20161128

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161114

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20160812

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160627

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160127

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20141014

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161226